Sarcoma uterino. Presentación de un caso


[1] Di Saia PJ, Creasman WT. Sarcomas of the uterus. En: Clinical Gynecologic Oncology. St. Louis: The CV Mosby Company; 1997. p. 169-79.

[2] Lurain JR, Piver MS. Uterine sarcomas: clinical features and manegement. En: Coppleson M. editor. Gynecologic Oncology Vol. II. Edimburgo. Churchill Livingston 1992. p. 827-40.

[3] Rose PG, Boutselis JG, Sacks L. Adjuvant therapy for stage I uterine sarcoma. Am J Obstet Gynecol 1987; 156: 660-2.

[4] Canavach D, Praphat H, Ruffold EH. Sarcomas of the uterus. Obstet Gynecol Ann 1979; 8: 413-8.

[5] Salazar OM, Bonfiglio RA, Patten SF, Keller BE, Feldstein M, Dunne ME, et al. Uterine sarcomas. Natural history, treatment and prognosis. Cancer 1978; 42: 1152-60.

[6] González-Bosquet E, Martínez-Palones JM, González-Bosquet J, García Jiménez A, Xercavins J. Uterine sarcoma: a clinicopathological study of 93 cases. Eur J Gynaecol Oncol 1997; 18: 192-5.

[7] Nordal RR, Thorensen SO. Uterine sarcomas in Norway 1956-1992: Incidence, survival and mortality. Eur J Cancer 1997;33: 907-11

[8] Bazzochi F, Brandi G, Pileri S, Mancuso A, Massaro A, Martinelli G. Clinical and pathologic prognostic features of leiomyosarcoma of the uterus. Tumori 1983. p. 69-75.

[9] Herruzo AJ, Rodríguez-Oliver A, Gómez T, Ruiz-Tallón F, Montoya F, Carmona M, et al. Sarcomas uterinos. Estudio de 31 pacientes. Clin Invest Gin Obst 1995; 22: 209-14.

[10] Laxman R, Currie JL, Kurman RJ, Dudzinski M, Griffin CA. Cytogenetic profile of uterine sarcomas. Cancer 1993; 71: 1283-8.

[11] Swisher EM, Gown AM, Skelly M, Ek M, Tamini HK, Cain JM, et al. The expresion of epidermal growth factor receptor, HER-2/neu, p53, and Ki-67 Antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996:60:81-8.

[12] Ansink AC, Cross PA, Scorer P, de-Barros-Lopes A, Monaghan JM. The hormonal receptor status of uterine carcinosarcomas (mixed mullerian tumours): an immunohistochemical study. J Clin Pathol 1997; 50: 328-31.

[13] Baggish MS, Woodruff JD. Uterine stromatosis. Clinicopathologic features and hormone dependency. Obstet Gynecol 1977; 40: 487-9.

[14] Abu-Rustum NR, Curtin JP, Burt M, Jones WB. Regression of uterine low-grade smooth-muscle tumors metastatic to the lung after oophorectomy. Obstet Ginecol 1997; 89: 850-2.

[15] Mark RJ, Poen J, Tran LM, Fu YS, Heaps J, Parker RG. Postirradiation sarcoma of the gynecologic tract. A report of 13 cases and a discussion of the risk of radiation-induced gynecologic malignancies. Am J Clin Oncol 1996;19:59-64

[16] Edward V Hannigan. Sarcomas uterinos. Copeland. Reimpresión de la edición 1996:1004-16.

[17]Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst 1986;76: 399.

[18] Meredith RF, Liskow AS, Crum CP, McCaffeym, et al. Uterine sarcomas: A clinicophatologic study, 1965-1981. Gynecol Oncol 1984; 18:299.

[19] Schwart SM, Thomas DB. The World Health Organization. Collaborative study of neoplasia and steroid contraceptives. Cancer 1989; 64:2487.

[20] Chen SS. Propensity of retroperitoneal lymph node metastasis in patients with Stage I sarcoma of the uterus. Gynecol Oncol 1989; 32:215.

[21] Leisbson SG, Mishell DR, Schlaerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyosarcomas. Am J Obstet Gynecol 1990; 17:123.

[22] Hannigan EV, Fredman RS, Elder KW, et al. Treatament of uterine sarcomas with Vincristine, Actinomicin D, and Cyclofosfamide. Gynecol Oncol 1983a; 15: 56.

[23] Nielson SN, Podratz KC, et al. Clinicopathologic analysis of uterine mixed mullerian tumors. Obstet Gynecol 1989; 34:372.

[24] Larson B, Silfversward C, Nilsson B, Petersson F. Mixed mullerian tumours of the uterus- Pronostic factors: A Clinical and histopatological study of 147 cases. Radiother Oncol 1990; 162: 298.

[25] Currie JL, Blessing JA, et al. Phase II trial of hydroxiurea, Dacarbacine and Etoposido in mixed mesodermal tumors of the uterus: A Gynecologic Oncology Group study. Gynecol Oncol 1996; 61: 94-6.

[26] Hornbak NB, Omura G, et al. Observations on the use of adyuvant radiation therapy in the treatament of stage I and II uterine sarcoma by Gynecologic Oncology group. Int Radiat Oncol Biol Phys 1986; 12: 2121-30.

[27] Francis JM, Blessing JA, et al. Pronostic factors in early-stage uterine sarcomas. Cancer 1993; 71: 1702-9.

[28] Swisher EM, Gown AM, Skelly M et al. The expression on epidermal growth factor receptor, HER-2/neu, P53, and Ki67 antigen in uterine malignant mixed mesodermal tumors and adenosarcoma. Gynecol Oncol 1996; 60; 81-8.